GSK Vaccines
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 8 disclosed transactions, GSK Vaccines concentrates its licensing activity in Oncology, Codev Deals, and Immunology. GSK Vaccines pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $5.1B. Most recent activity: 2026.
Pipeline coverage & gaps
GSK Vaccines has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 3 | $243M | $1.3B |
| AcquisitionPrimary | 3 | $1.0B | $4.2B |
| Option | 1 | $500M | $12.0B |
| Collaboration | 1 | — | $12.0B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | risvutatug rezetecan (ris-rez) / HS-20093 | Hansoh Pharmaceutical | small cell lung cancer | phase_3 | $185M | $1.7B |
| 2026 | siRNA obesity program | Siran Biotechnology | obesity and metabolic disease | preclinical | $1.0B | $1.0B |
| 2025 | PDE3/4 inhibitor (COPD) plus 11 additional programs | Hengrui Pharma | COPD | unknown | $500M | $12.0B |
| 2025 | oncology portfolio (~12 programs) | Jiangsu Hengrui | oncology | unknown | — | $12.0B |
| 2025 | Nuvalent pipeline (ALK/ROS1 kinase inhibitors) | Nuvalent, Inc. | ALK-positive and ROS1-positive lung cancer and solid tumors | phase_2 | — | $10.6B |
| 2024 | CMG-1A46 | Chimagen | lupus | preclinical | $300M | $850M |
| 2024 | HS-20089 | Hansoh | — | unknown | — | $1.3B |
| 2024 | AIO-001 (anti-TSLP) | Aiolos Bio | asthma | phase_1 | $1.0B | $1.0B |
How this is computed
For each GSK Vaccines deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.674, clamped to [0.7, 1.5].